NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Department of Cardiology, National University of Ireland Galway (NUIG), Galway, Ireland; Department of Cardiology, Imperial College of London, London, United Kingdom.
Am J Cardiol. 2021 Mar 15;143:21-28. doi: 10.1016/j.amjcard.2020.12.039. Epub 2021 Jan 5.
Prior studies in patients with noncomplex coronary artery disease have demonstrated the safety of percutaneous coronary intervention (PCI) in the outpatient setting. We sought to examine the outcomes of outpatient PCI in patients with unprotected left main coronary artery disease (LMCAD). In the EXCEL trial, 1905 patients with LMCAD and site-assessed low or intermediate SYNTAX scores were randomized to PCI with everolimus-eluting stents versus coronary artery bypass grafting. The primary end point was major adverse cardiovascular events (MACE; the composite of death, stroke, or myocardial infarction). In this sub-analysis, outcomes at 30 days and 5 years were analyzed according to whether PCI was performed in the outpatient versus inpatient setting. Among 948 patients with LMCAD assigned to PCI, 935 patients underwent PCI as their first procedure, including 100 (10.7%) performed in the outpatient setting. Patients who underwent outpatient compared with inpatient PCI were less likely to have experienced recent myocardial infarction. Distal left main bifurcation disease involvement and SYNTAX scores were similar between the groups. Comparing outpatient to inpatient PCI, there were no significant differences in MACE at 30 days (4.0% vs 5.0% respectively, adjusted OR 0.52 95% CI 0.12 to 2.22; p = 0.38) or 5 years (20.6% vs 22.1% respectively, adjusted OR 0.72, 95% CI 0.40 to 1.29; p = 0.27). Similar results were observed in patients with distal left main bifurcation lesions. In conclusion, in the EXCEL trial, outpatient PCI of patients with LMCAD was not associated with an excess early or late hazard of MACE. These data suggest that outpatient PCI may be safely performed in select patients with LMCAD.
先前针对非复杂性冠状动脉疾病患者的研究表明,经皮冠状动脉介入治疗(PCI)在门诊环境下是安全的。我们旨在研究无保护左主干冠状动脉疾病(LMCAD)患者门诊 PCI 的结果。在 EXCEL 试验中,1905 例 LMCAD 患者和经评估为低或中 SYNTAX 评分的患者被随机分配至接受依维莫司洗脱支架 PCI 或冠状动脉旁路移植术。主要终点为主要不良心血管事件(MACE;死亡、卒中和心肌梗死的复合终点)。在这项亚分析中,根据 PCI 是在门诊还是住院环境下进行,分析了 30 天和 5 年时的结局。在被分配至 PCI 的 948 例 LMCAD 患者中,935 例患者接受了 PCI 作为其首次治疗,其中 100 例(10.7%)在门诊环境下进行。与住院 PCI 相比,门诊 PCI 患者近期心肌梗死发生率较低。两组患者的左主干远段分叉病变和 SYNTAX 评分相似。与住院 PCI 相比,门诊 PCI 组在 30 天(分别为 4.0%和 5.0%,调整后的 OR 0.52,95%CI 0.12 至 2.22;p=0.38)或 5 年(分别为 20.6%和 22.1%,调整后的 OR 0.72,95%CI 0.40 至 1.29;p=0.27)时,MACE 无显著差异。在左主干远段分叉病变患者中也观察到了类似的结果。总之,在 EXCEL 试验中,LMCAD 患者的门诊 PCI 并不增加早期或晚期 MACE 的风险。这些数据表明,门诊 PCI 可能可以安全地用于特定的 LMCAD 患者。